Show simple item record

dc.contributor.authorPerini, Guilherme Fleurypt_BR
dc.contributor.authorFischer, Thais Rodrigues da Cunhapt_BR
dc.contributor.authorGaiolla, Rafael Dezenpt_BR
dc.contributor.authorFogliatto, Laura Mariapt_BR
dc.contributor.authorChiattone, Carlos Sérgiopt_BR
dc.date.accessioned2020-09-23T04:02:13Zpt_BR
dc.date.issued2020pt_BR
dc.identifier.issn2531-1379pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/213634pt_BR
dc.description.abstractThe novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofHematology, transfusion and cell therapy. Rio de Janeiro. vol. 42, no.2 (2020), p. 103-11pt_BR
dc.rightsOpen Accessen
dc.subjectInfecções por coronaviruspt_BR
dc.subjectCoViden
dc.subjectLinfomapt_BR
dc.subjectCoVId-19en
dc.subjectCoronavirusen
dc.subjectLeucemia linfocítica crônica de células Bpt_BR
dc.subjectLymphomaen
dc.subjectChronic lymphocytic leukemiaen
dc.subjectLymphoid malignanciesen
dc.titleHow to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak : a Brazilian task force recommendationpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001116663pt_BR
dc.type.originNacionalpt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record